Mary O’Hearn

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

Jacob Lalezari, Keith Henry, Mary O’Hearn et al. · New England Journal of Medicine · 2003 · 915 citations · Full text

Life Sciences, Pharmacokinetics, Pharmacotherapy +16

Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials

Mark Nelson, Keikawus Arastéh, Bonaventura Clotet et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2005 · 151 citations

Pharmacy, Internal Medicine, Pharmacotherapy +17

Fatal Lactic Acidosis and Acute Renal Failure after Addition of Tenofovir to an Antiretroviral Regimen Containing Didanosine

Melissa Murphy, Mary O’Hearn, Sunwen Chou · Clinical Infectious Diseases · 2003 · 109 citations · Full text

Medicine, Nephrology, Pharmacology +17

Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks

Benoît Trottier, Sharon Walmsley, Jacques Reynes et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2005 · 81 citations

Pharmacy, Pharmacotherapy, Infectious Disease Pharmacotherapy +14

PREGNANCY-INDUCED ALTERATIONS IN GRAFT-VERSUS-HOST RESPONSIVENESS OF UTERINE-DRAINING AND PERIPHERAL LYMPH NODE CELLS TOWARD FETAL ALLOANTIGENS

Mary O’Hearn, Henry R. Hilgard · Transplantation · 1981 · 18 citations

Life Sciences, Cell Biology, Immunology +13